Investigations

GRABAR LAW OFFICE INVESTIGATES CLAIMS AGAINST EXECUTIVES OF BOSTON SCIENTIFIC CORP. (NYSE: BSX)

WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Boston Scientific is a global company that develops, manufactures, and markets medical devices used across various specialties. Among the specialty market segments, the Company has an Electrophysiology (“EP”) business unit that develops and manufactures products used in the detection and treatment of heart rate and rhythm disorders. The key product offering Boston Scientific provides under this segment is the Farapulse PFA system.

According to a recently filed federal securities fraud class action lawsuit, Boston Scientific Corporation (NYSE: BSX), through certain of its officers, created the false impression that the Company possessed reliable information pertaining to the Company’s projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations. In truth, Boston Scientific’s ambition of continuing “to grow our share in the overall EP market” to maintain a growth trajectory at “2x the market” had fallen short of reality; the Company had begun to experience new competition entrants that were sapping Boston Scientific’s U.S. Electrophysiology market share and thus limiting the Company’s growth potential.

The truth emerged when, on February 4, 2026, before market open, Boston Scientific published a press release announcing fourth quarter and full year 2025 results that fell far shy of the company’s previously issued guidance in which Defendants continually raised associated fiscal 2025 guidance targets, claiming heightened confidence in the U.S. EP division’s growth trajectory, while continually minimizing risks associated with competition, seasonality and the potential impact of the macro environment on future profitability.

WHAT YOU CAN DO NOW: If you purchased Boston Scientific (NYSE: BSX) shares prior to July 23, 2025, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased Boston Scientific shares between July 23, 2025 and February 3, 2026, you can participate in the class action.

#BostonScientific #BSX $BSX

Attorney Advertising Disclaimer

Comments
This field is for validation purposes and should be left unchanged.
Join This Action
Name*
First Last
Email Address*
Address*
Street Address City State / Province / Region ZIP / Postal Code
Phone*
Stock Name or Ticker
Number of Shares Purchased
Date(s) Shares Purchased
Purchase Price Per Share
Number of Shares Sold
Date(s) Shares Sold
Sale Price Per Share
Comments
Alternatively, you may upload your transactions using the upload button below or email them to jgrabar@grabarlaw.com. *
File
Drop files here or

Max. file size: 512 MB.
Consent*
By signing and clicking the Submit button below, I hereby execute the Retention Agreement and, upon execution of the Retention Agreement by Grabar Law Office, retain Grabar Law Office to make a demand and bring any ensuing lawsuit on my behalf pursuant to the terms set forth in the Retention Agreement, which is incorporated herein by reference.*
Please sign below using your mouse or touch-pad.*
Signed pursuant to California Civil Code Section 1633.1, et seq. and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.
Date of signing: *
Date of signing:*
MM slash DD slash YYYY

Investigations

GRABAR LAW OFFICE INVESTIGATES CLAIMS AGAINST EXECUTIVES OF BOSTON SCIENTIFIC CORP. (NYSE: BSX)

Join This Action